Board of Directors
Andy Richards CBE
Dr. Andy Richards CBE is a well-established entrepreneur and builder of biotechnology, healthcare and diagnostic ventures. He brings a strong business focus and an in-depth knowledge of the industry and company scale up. In addition to Abcodia he is also currently Chairman of Congenica, Closed Loop Medicine and Arecor and a Director of Owlstone Medical and Ieso Digital Health. He is Chairman of the Babraham Research Campus and a director of Cancer Research Technology Ltd (the commercial board of Cancer Research UK). His early career spanned positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive director of Chiroscience. Andy is a graduate of Cambridge University with a PhD in Chemistry and a track record as a founder, active investor in and director of more than 25 innovative healthcare and life-science companies, including Vectura plc and Arakis Ltd. Andy is also a founder member of the Cambridge Angels.
Julie Barnes, PhD.
Julie has over 30 years of experience in Life Sciences, working in both public and private companies. She spent 15 years in pharmaceutical R&D, latterly with GlaxoSmithKline as Head of Neuroscience (1996-2001). Since then she has assumed several roles in small venture-backed companies active in software, medical device development and drug development, where she has lead scientific, regulatory and commercial strategy. In 2013, she won the WISE (Women in Science and Engineering) Award for Enterprise and Innovation.
Chris has over 25 years’ experience in finance and has held senior positions at a variety of organization types, ranging from business start-ups to a FTSE 250 company. He joined Abcodia as CFO in October 2015. Before joining the company Chris was CFO at Zinwave Ltd, steering the company to its sale in 2014. He was the Finance Director at Enecsys Ltd. and played a fundamental role in numerous fund raising activities, (including Series B for $41m) to support the global growth of the organization.
Andrew is lead healthcare partner at Albion Ventures. Following biomedical research, he qualified as a surgeon, specializing in neurosurgery. He then joined the Boston Consulting Group (BCG) where he specialized in healthcare strategy, gaining experience with many large, global clients across the full spectrum of healthcare including biotechnology, pharmaceuticals, service and care providers, software and telecommunications. He oversees Albion Ventures’ broad range of healthcare investing, from care provision to life science services, imaging and diagnostics.
Jan is a Partner and member of the investment committee at Scottish Equity Partners (SEP), where she leads investments in high growth technology companies and oversees investments across the healthcare sector. A venture capital investor for the past 15 years, Jan joined SEP in 2004 from Dresdner Kleinwort Capital. Prior to moving into the investment field, she held operational and commercial roles in the pharmaceutical industry for, Merck, Novartis and Quintiles.
Robert joined Cambridge Innovation Capital as the Investment Director for Life Sciences in January 2014 after 20 years’ experience in the pharma/biotech industry working both at large pharma (Sanofi, Roche), the MHRA and in VC backed companies (Arakis, KalVista) including founding the malaria therapeutics company Treague and as founding CEO of Avilex Pharma. Robert qualified in medicine at University College London; he is a member of the Royal College of Obstetricians and Gynecologists and the Faculty of Pharmaceutical Medicine. He has an MBA from London Business School and an MPhil in Biostatistics from the University of Cambridge.
Richard A. Sandberg
Dick has played a principal role in starting and building a number of medical diagnostic companies including that of founder, chairman, chief executive officer, and chief financial officer of DIANON Systems Inc.. He also served as chairman and chief financial officer of Lifecodes Corporation, a pioneer in DNA testing technology; chief financial officer and director of Matritech Inc., a company specializing in proteomic diagnostic products for the early detection of a variety of cancers. He is currently a Director of Oxford Immunotec a global diagnostics company providing advanced, innovative tests in the field of immunology.
Professor Ian Jacobs
Ian is currently President and Vice-Chancellor of University of New South Wales, Sydney Australia. Prior to this, he was Vice President of the University of Manchester from 2011-15 and Dean of Medicine and University College London from 2009-11. He qualified in medicine at Cambridge University and the University of London before specialising in surgical treatment of women’s cancers. He has for the last 30 years led a research team working on early detection and risk prediction of cancer with a particular focus on screening for ovarian cancer, which has led to grant awards > £50m and over 400 publications. He was the lead investigator for the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).